Biotech · Private company
Myriad Genetic Laboratories, Inc.
Track this companyFree. Adds Myriad Genetic Laboratories, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials205 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- Diagnostic testHereditary CancerClinicalTrials.gov · fetched Nov 12, 2026
- Diagnostic test (LDT)Major Depressive Disorder, Bipolar I and Bipolar IIClinicalTrials.gov · fetched Nov 12, 2026
- ObservationalPrimary Invasive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pharmacokinetic 5-FU dose adjustment using OnDose® assayColorectal Cancer, MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- ProlarisProstate CancerClinicalTrials.gov · fetched Nov 12, 2026
- Prolaris TestingProstate CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials20
- Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® TestingACTIVE_NOT_RECRUITING · started Apr 30, 2020ClinicalTrials.gov NCT04404894 · fetched Nov 12, 2026
- EndoPredict® Extended Endocrine Trial (EXET)TERMINATED · started Jul 2, 2019ClinicalTrials.gov NCT04016935 · fetched Nov 12, 2026
- A Registry for Hereditary Cancer Risk Assessment and Genetic TestingCOMPLETED · started Mar 6, 2019ClinicalTrials.gov NCT04015102 · fetched Nov 12, 2026
- Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer PatientsPHASE3 · ACTIVE_NOT_RECRUITING · started Jan 4, 2019ClinicalTrials.gov NCT03737643 · fetched Nov 12, 2026
- Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® TestingCOMPLETED · started Mar 12, 2018ClinicalTrials.gov NCT03511235 · fetched Nov 12, 2026
- Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate CancerTERMINATED · started Sep 14, 2017ClinicalTrials.gov NCT03290508 · fetched Nov 12, 2026
- Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian CancerPHASE2 · COMPLETED · started Jan 17, 2017ClinicalTrials.gov NCT02889900 · fetched Nov 12, 2026
- Bipolar Proteomic Assay Validation StudyCOMPLETED · started Mar 1, 2016ClinicalTrials.gov NCT02746367 · fetched Nov 12, 2026
- Combined Breast Cancer Risk StudyCOMPLETED · started Feb 6, 2016ClinicalTrials.gov NCT03067389 · fetched Nov 12, 2026
- The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid TumorsPHASE1 · COMPLETED · started Feb 2, 2016ClinicalTrials.gov NCT02660034 · fetched Nov 12, 2026
- Prospective Prolaris Value and EfficacyTERMINATED · started Sep 1, 2015ClinicalTrials.gov NCT03152448 · fetched Nov 12, 2026
- Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum TreatmentsPHASE3 · COMPLETED · started Feb 6, 2015ClinicalTrials.gov NCT02282020 · fetched Nov 12, 2026
- Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyPHASE3 · COMPLETED · started Dec 16, 2014ClinicalTrials.gov NCT02184195 · fetched Nov 12, 2026
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Apr 22, 2014ClinicalTrials.gov NCT02032823 · fetched Nov 12, 2026
- Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.PHASE3 · COMPLETED · started Mar 27, 2014ClinicalTrials.gov NCT02000622 · fetched Nov 12, 2026
- A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsPHASE3 · TERMINATED · started Feb 25, 2014ClinicalTrials.gov NCT01905592 · fetched Nov 12, 2026
- A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)PHASE2 · TERMINATED · started Dec 13, 2013ClinicalTrials.gov NCT02034916 · fetched Nov 12, 2026
- Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyPHASE3 · ACTIVE_NOT_RECRUITING · started Sep 3, 2013ClinicalTrials.gov NCT01874353 · fetched Nov 12, 2026
- Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.PHASE3 · ACTIVE_NOT_RECRUITING · started Aug 26, 2013ClinicalTrials.gov NCT01844986 · fetched Nov 12, 2026
- Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6PHASE4 · TERMINATED · started Sep 1, 2011ClinicalTrials.gov NCT01468623 · fetched Nov 12, 2026